Article

Latanoprost joins Pfizer's prescription card plan

New York-With the recent acquisition of Pharmacia Corp., Pfizer Inc. is making latanoprost ophthalmic solution (Xalatan) and three non-ophthalmic medicines available at a reduced cost to qualified senior citizens.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) CCOI sets the stage for global ophthalmic innovation at Stanford Summit on July 23
(Image credit: Ophthalmology Times) Accelerating eye health innovation through CCOI – Stanford Summit
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
Related Content
Alkeus Pharmaceuticals to present TEASE and SAGA study data at ASRS 2025
July 27th 2025

Alkeus Pharmaceuticals to present TEASE and SAGA study data at ASRS 2025

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Most Americans avoid eye exams due to perceived non-urgency, confusion about benefits
July 26th 2025

Most Americans avoid eye exams due to perceived non-urgency, confusion about benefits

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

(Image credit: AdobeStock/Bonsales) Q&A: Natalie Afshari, MD, FACS, on-label pediatric IOLs: turning advocacy into access
July 24th 2025

Q&A: Natalie Afshari, MD, FACS, championing on-label pediatric IOLs: turning advocacy into access

Annexon completes enrollment in phase 3 ARCHER II trial of vonaprument for geographic atrophy
July 24th 2025

Annexon completes enrollment in phase 3 ARCHER II trial of vonaprument for geographic atrophy

© 2025 MJH Life Sciences

All rights reserved.